+91 80 2808 2808
Biocon Biologics  /  About Us


Transforming Lives Through Meaningful Impact

Sharp inequalities in access to advanced therapies have denied the benefits from progress in medical science to almost a third of the world’s population. Hefty price tags on life-saving drugs have created unbearable financial burden for patients in most of the world. Inadequate research spending has led to a fragile medical innovation ecosystem with serious repercussions on global preparedness for health emergencies.

COVID-19 served as a wake-up call for the global pharmaceutical sector, forcing the community to rapidly innovate and rethink new ways of improving access to essential, lifesaving medicines.

Biosimilars can improve patient access to quality medicines

Biosimilars can Improve Patient Access to Quality Medicines

Biosimilars are versions of brand name biologics that may offer more affordable treatment options to patients, like generic drugs. Biosimilars are intended to increase patients’ access to biologics as they are priced lower than branded, novel biologics and may further lead to the competitive pricing of the original biologic.

Biosimilars can ensure a greater and more equitable access to biologic therapies and to healthcare generally. With over 400 biosimilar approvals today in key therapeutic areas for diseases such as autoimmune disorders, cancers, genetic disorders, and diabetes, the biosimilars potential in supporting universal access to medicines (UN SDGs 2030) remains largely untapped.

Our Global Scale Capabilities


Our Factsheet

Driven by a Purpose to Address Unmet Needs for Affordable Biologics

Healthcare systems across the world are skewed towards serving the affluent, denying access to many. Biocon Biologics is challenging the status quo by putting ‘patients first’ to make a long-term social impact worldwide.

We are driven by a strong sense of purpose and the unwavering commitment to deliver on our vision to transform healthcare. To achieve our vision, we are leveraging our affordable innovation model to reduce disparities in access to safe, high-quality medicines, as well as improve patient outcomes and provide global communities with differentiated, high-quality and affordable healthcare solutions.

Our business model seeks to make biologic therapies affordable, accessible and available to all, thereby benefiting patients and their families across the world.

Our roadmap for the future is to enable a healthier world.

Exploring Possibilities to Make a Meaningful Difference

Biocon Biologics is leveraging new operating models that facilitate access to lifesaving therapies for all.

As a global company focused exclusively on affordable biologics with full vertical integration, we are uniquely positioned to achieve this ambition.

Our 40-year legacy of being at the cutting edge of science has enabled us to simultaneously build a global scale with a competitive cost structure.

We have made significant investments in R&D to build a wide biosimilars portfolio. We have channeled our capital expenditure towards building global scale manufacturing capacity. We have also prudently enhanced our commercial footprint to reach more patients.

Exploring Possibilities to Make a Meaningful Difference

Passion to Impact Global Health

Our passion for impacting global healthcare has led us to build a diverse portfolio of products straddling monoclonal antibodies and other conjugated recombinant proteins for cancer and autoimmune diseases, as well as human insulin and insulin analogs for diabetes.

Our continued commitment to quality and product safety, positions us to continually innovate to shape the biosimilars market to serve the unmet needs of healthcare systems globally.

A Partner of Choice

A Partner of Choice

Biocon Biologics has a proven track record of scientific capabilities, large scale manufacturing capacities and a strong supply & distribution network in compliance with the highest standards of quality and governance. We hold ourselves to the highest standards of ethics and compliance in our relentless pursuit to make a real difference. We are lowering treatment costs and improving healthcare outcomes whilst delivering shareholder value and on the business objectives.

Protecting the Health of our Planet

While pursuing our purpose of using biotechnology to develop therapies that heal the world, Biocon Biologics is equally concerned about the health of our planet and the deteriorating ecological balance.

As a responsible corporate citizen, we have designed our operations to enable environmental sustainability with a low carbon footprint while ensuring maximum recycling of wastewater and the use of green power.

Supporting environmental and health equity is our commitment to diversity and inclusion at the workplace. We have consistently endeavored to create a collaborative and empowering work culture, when building businesses that make a meaningful social impact.

We have established globally benchmarked standards of governance to build an environment of trust, transparency and accountability necessary for fostering long-term investment, financial stability and business integrity, thereby supporting a stronger growth and more inclusive societies.